Although research has shown that authorized COVID-19 vaccines generate a strong antibody response, their effectiveness has not yet been evaluated in those taking immunosuppressants to treat diseases such as lupus, arthritis, psoriasis and Crohn’s. In a recent KSDK story, Alfred Kim, MD, PhD, assistant professor of medicine, says that this uncertainty led him to start a clinical trial to evaluate the antibody response in such patients. Kim is currently recruiting health-care workers at WashU Med and patients seen in Washington University outpatient clinics.
He strongly encourages patients on immunosuppressants to get vaccinated, as they have a higher risk of experiencing serious complications of COVID-19.
For more information about participating in the trial, email email@example.com.